<DOC>
	<DOC>NCT00237809</DOC>
	<brief_summary>This study is based on the hypothesis that by increasing N-methyl-D-aspartic acid (NMDA) receptor function in the brain and thereby increasing the capacity of the brain to both form new connections and strengthen existing connections, schizophrenic patients may derive both greater and sustained benefit from cognitive retraining.</brief_summary>
	<brief_title>D-Serine Treatment of Negative Symptoms and Cognitive Deficits in Schizophrenia</brief_title>
	<detailed_description>Patients with schizophrenia or schizoaffective disorder who are currently receiving antipsychotic medication will be randomly assigned in a double-blind manner to receive either D-serine (30 mg/kg) or placebo in addition to cognitive rehabilitation or a non-interactive placebo for 12 weeks.</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Cognition Disorders</mesh_term>
	<criteria>Diagnosis of schizophrenia or schizoaffective disorder Exclusion Pregnant or lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>